Por favor, use este identificador para citar o enlazar este ítem: https://hdl.handle.net/20.500.12104/42011
Título: Hyperhomocysteinemia in ankylosing spondylitis: Prevalence and association with clinical variables
Autor: Gonzalez-Lopez, L.
Sanchez-Hernandez, J.D.
Aguilar-Chavez, E.A.G.
Cota-Sanchez, A.R.
Lopez-Olivo, M.A.
Villa-Manzano, A.I.
Ortega-Flores, R.
Espinoza-Magana, G.L.
Rojo-Contreras, W.
Cardona-Munoz, E.G.
Gamez-Nava, J.I.
Fecha de publicación: 2008
Resumen: We evaluated the prevalence and characteristics associated with hyperhomocysteinemia in ankylosing spondylitis (AS). Ninety-seven patients with AS were compared with 97 controls. The assessment included clinical characteristics, disease activity (BASDAI), functioning (BASFI), history of drugs, and erythrocyte sedimentation rate (ESR). Total serum homocysteine (tHcy) was determined by fluorescence polarization immunoassay. A higher frequency of hyperhomocysteinemia (>15 ?mol/L) was observed in AS (12 vs. 1%, P = 0.002). In the multivariate analysis the risk for hyperhomocysteinemia was increased in patients with higher score of HAQ-S (OR = 5.27, 95% CI: 1.29-21.44) and higher ESR (OR = 1.09, 95% CI: 1.02-1.18). No statistical associations was observed between hyperhomocysteinemia with other variables including methotrexate or sulfasalazine utilization. In conclusion, this study found a significant prevalence of hyperhomocysteinemia in Mexican patients with AS mainly associated to a worst functional impairment. Further follow-up studies are required to evaluate the risk of cardiovascular disease in these patients. � 2008 Springer-Verlag.
URI: http://www.scopus.com/inward/record.url?eid=2-s2.0-51649102976&partnerID=40&md5=659bcf6c9e33cbd53caba5f8bd09deed
http://hdl.handle.net/20.500.12104/42011
Aparece en las colecciones:Producción científica UdeG

Ficheros en este ítem:
No hay ficheros asociados a este ítem.


Los ítems de RIUdeG están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.